Oncotarget: A Scion of Open Access Peer-reviewed Journalism

Since its founding in 2010. Oncotarget has carved out a name for itself as one of the leading peer-reviewed journals globally. Its Impact Factor (IF) as measured by Thomson Reuters JCR has risen from 4.784 in 2011 to 5.168 in the 2016/2017 grading year. Between 2011 and 2016, Oncotarget’s citations have increased over 20 times from 493 to 10,452. The journal’s five-year Impact Factor stands at 5.415 as of 2015/2016 ratings. It has been given the highest ranking, Q1, by Scopus/SJR for its excellent contributions in medicine and oncology. This growing popularity informed the journal’s decision to expand the fields to be covered by the articles to be included in its publications. The fields have expanded from oncology to other fields including cell biology, pharmacology, neuroscience and cardiology. It also accepts papers on metabolism and endocrinology among other fields. Learn more about Oncotarget at Research Gate.

Journal Profile: Success Factors

Oncotarget is published weekly by Impact Journals in English. The medicine journal is peer reviewed by its highly experienced editorial board members and editors. The over a hundred editors and editorial board members are specialists in a wide range of fields including pathology, oncology, aging, immunology and microbiology, and cell biology. Some of them such as Andrew Schally are excellent research scientists who have been honored with the prestigious Nobel Prize. The excellent service delivery by the journal’s editorial board was recognized in 2013 when four members were honored with the Breakthrough Prize. These individuals have brought their experience and expertise to Oncotarget and helped the journal build a strong reputation rapidly. Others such as Mikhail Blagosklonny and Andrei V. Gudkov, who are the founding editors-in-chief, are experienced research scientists who have led cancer research for many years.

As an open access, Oncotarget accepts articles from authors around the world. It is an indication of its commitment towards knowledge and information dissemination with the view of meeting the ultimate goal of a world free from diseases. Its free access policy has also driven its popularity especially within scientific communities. Moreover, the journal’s success can also be attributed to its multidisciplinary nature. Covering numerous disciplines ensures that the journal’s impact factor and citations increase significantly. Check Oncotarget journal at scimagojr.com

Dr. JeanMarie Guenot Lends Her Experience to Amphivena Therapeutics

 

Amphivena Therapeutics, a developer of immunotherapeutics, is on a mission to eradicate blood cancers. Their goal is to restore the flow of life by reestablishing cellular balance. Amphivena Therapeutics believes that if blood is forming, functioning, and circulating properly then the body’s immune system will destroy tumors along with their precursors.

The San Francisco-based company, founded in 2013, is currently in the pre-clinical stage of development. Amphivena Therapeutics INC. is an innovative company that formed relationships with world renowned industry and academic associates. They are committed to giving patients suffering from hematologic malignancies the best treatment options available.

Leading the company’s foray into unchartered immunotherapy territory is the incredible JeanMarie Guenot, Ph.D. Dr. Guenot is the current President and CEO of Amphivena Therapeutics. She has 20 years of experience in both the biotechnology and the pharmaceutical industry. JeanMarie Guenot also has an unprecedented amount of experience in building and rebuilding companies. Something that will most likely prove to be invaluable to an innovator like Amphivena.

JeanMarie Guenot began her education at the University of California, San Francisco, where she studied medicinal chemistry, physical chemistry, quantum mechanical and semi-empirical methods for molecular dynamics, protein structure prediction, X-ray and NMR refinement and drug design. She received her Ph.D. and went on to study at the University of Pennsylvania’s prestigious Wharton School, where she earned her MBA.

JeanMarie’s biography makes it clear that after being employed as a venture capital investment manager and life science company developer at Atlas Venture, and as a principal scientist at Hoffmann-La Roche, Dr. Guenot founded SKS Ocular. SKS Ocular is a start-up ophthalmic company incubator, focused on sustained release ocular drug delivery technologies, dry AMD, and glaucoma, macular degeneration and ocular inflammation therapies.

Dr. Guenot is clearly passionate about her life’s work. She’s capable of leading Amphivena Therapeutics to the forefront of immunotherapeutics.   Read more about Guenot’s work with Amphivena on Newson6.